Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1866 - Role of body composition in early stage colorectal cancer (CRC) outcomes

Date

09 Sep 2017

Session

Poster display session

Presenters

Jessica Hopkins

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

J. Hopkins1, D. Bigam2, D. Eurich3, V. Baracos4, M. Sawyer5

Author affiliations

  • 1 Department Of Surgery, University of Alberta, T6G2B7 - Edmonton/CA
  • 2 Department Of Surgery, University of Alberta, Edmonton/CA
  • 3 School Of Public Health, University of Alberta, Edmonton/CA
  • 4 Department Of Oncology, Division Of Palliative Care Medicine, Department of Oncology, Division of Palliative Care Medicine, Alberta/CA
  • 5 Medical Oncology, Cross Cancer Institute, University of Alberta, T6G1Z2 - Edmonton/CA
More

Resources

Abstract 1866

Background

CRC is the 3rd most common cancer worldwide. Novel prognostic factors are needed to allow practitioners to stratify and personalize treatment and surveillance options to patients (pts). The objective of this study was to determine associations between body composition and disease-specific outcomes in early stage CRC. We hypothesized that pts with sarcopenia or reduced muscle radiodensity (SMD) at time of surgery will have worse overall outcomes, specifically in their 5-year overall (OS) and disease free survival (DFS). Also, that pts with accelerated skeletal muscle loss at their 2-year surveillance computed tomography (CT) scan will have higher recurrence rates.

Methods

This is a retrospective cohort study of early stage (I-III) CRC from 2007-09. We excluded any pt without analyzable or preoperative CT scan or if a prior diagnosis of CRC. Routine CT imaging was used to measure skeletal muscle (SMA). Total body SMA was normalized for height (skeletal muscle index, SMI). An SMI

Results

A total of 2049 pts were identified, of which 1455 had available, analyzable imaging. The cohort was 59% male. The median age was 67 yrs with over 50% older than 65. Most pts presented with stage II-III disease (39%, 50%, respectively). The prevalence of sarcopenia was 45.0% in females and 56.2% in males, with an average SMI of 40 and 51 cm2/m2, respectively. Average SMD was 31.5 HU for females and 33.2 HU for males. Pts with disease recurrence had a significantly lower SMI (49 vs. 42 cm2/m2, p 

Conclusions

Our study demonstrates for the first-time body composition’s ability to predict recurrence of a solid tumor after curative surgery. Pts with reduced overall SMI and SMD had increased risks of disease recurrence. These findings if validated may allow better stratification of treatment and surveillance of CRC pts.

Clinical trial identification

Legal entity responsible for the study

University of Alberta

Funding

Clinical Investigator Program - Alberta Health Flex

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings